Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients.

Détails

Ressource 1Télécharger: serval:BIB_FB953C5B3D78.P001 (136.76 [Ko])
Etat: Public
Version: de l'auteur
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_FB953C5B3D78
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients.
Périodique
Journal of Antimicrobial Chemotherapy
Auteur(s)
Perrottet N., Robatel C., Meylan P., Pascual M., Venetz J.P., Aubert J.D., Berger M.M., Decosterd L.A., Buclin T.
ISSN
1460-2091[electronic], 0305-7453[linking]
Statut éditorial
Publié
Date de publication
2008
Volume
61
Numéro
6
Pages
1332-1335
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't
Résumé
OBJECTIVES: To determine whether valganciclovir 450 mg every 48 h for cytomegalovirus (CMV) prophylaxis provides appropriate ganciclovir exposure in solid organ transplant recipients during continuous renal replacement therapy (CRRT).
PATIENTS AND METHODS: Ganciclovir pharmacokinetics was intensively studied in two lung transplant recipients under valganciclovir 450 mg every 48 h over one dosing interval. In vitro experiments using blank whole blood spiked with ganciclovir further investigated exchanges between plasma and erythrocytes.
RESULTS: Ganciclovir disposition was characterized by apparent total body clearance of 3.3 and 5.8 L/h, terminal half-life of 16.9 and 14.1 h, and apparent volume of distribution of 60.3 and 104.9 L in Patients 1 and 2, respectively. The observed sieving coefficient was 1.05 and 0.96, and the haemofiltration clearance was 3.3 and 3.1 L/h. In vitro experiments confirmed rapid efflux of ganciclovir from red blood cells into plasma, increasing the apparent efficacy of haemofiltration.
CONCLUSIONS: A valganciclovir dosage of 450 mg every 48 h appears adequate for patients under CRRT requiring prophylaxis for CMV infection, providing concentration levels in the range reported for 900 mg once daily dosing outside renal failure.
Mots-clé
Chemoprevention/methods, Cytomegalovirus Infections/prevention & control, Ganciclovir/administration & dosage, Ganciclovir/analogs & derivatives, Half-Life, Humans, Lung Transplantation, Male, Metabolic Clearance Rate, Middle Aged, Renal Replacement Therapy
Pubmed
Web of science
Open Access
Oui
Création de la notice
29/01/2009 22:13
Dernière modification de la notice
25/09/2019 6:11
Données d'usage